Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Cash from Investing Activities: 2013-2025

Historic Cash from Investing Activities for Theravance Biopharma (TBPH) over the last 13 years, with Sep 2025 value amounting to -$100.2 million.

  • Theravance Biopharma's Cash from Investing Activities fell 476.16% to -$100.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.2 million, marking a year-over-year decrease of 2110.98%. This contributed to the annual value of $12.3 million for FY2024, which is 137.57% up from last year.
  • Theravance Biopharma's Cash from Investing Activities amounted to -$100.2 million in Q3 2025, which was down 176.48% from -$36.3 million recorded in Q2 2025.
  • Theravance Biopharma's 5-year Cash from Investing Activities high stood at $1.1 billion for Q3 2022, and its period low was -$100.2 million during Q3 2025.
  • For the 3-year period, Theravance Biopharma's Cash from Investing Activities averaged around -$11.5 million, with its median value being -$677,000 (2023).
  • As far as peak fluctuations go, Theravance Biopharma's Cash from Investing Activities skyrocketed by 3,104.52% in 2022, and later crashed by 82,752.38% in 2024.
  • Over the past 5 years, Theravance Biopharma's Cash from Investing Activities (Quarterly) stood at $10.8 million in 2021, then soared by 261.80% to $39.2 million in 2022, then crashed by 101.73% to -$677,000 in 2023, then surged by 2,416.99% to $15.7 million in 2024, then slumped by 476.16% to -$100.2 million in 2025.
  • Its last three reported values are -$100.2 million in Q3 2025, -$36.3 million for Q2 2025, and $30.6 million during Q1 2025.